Author

Mona Mohammad Almramhi

King Abdulaziz UniversityORCID 0000-0002-4370-373XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Genetic & Genomic Medicine· 1 Genetics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:GWAS summary statistics· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:benchmarking· 1 Research Focus:drug response / drug discovery· 1 Research Focus:GWAS / association mapping· 1

Frequent Co-Authors

Aroon Dinesh HingoraniiD· 2 shared Catherine S. StormiD· 2 shared Chris FinaniD· 2 shared Demis A. Kia· 2 shared Nicholas William WoodiD· 2 shared Amand Floriaan SchmidtiD· 1 shared Rachel ConeysiD· 1 shared Sandesh ChopadeiD· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

9 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenetic & Genomic Medicine

Aroon Dinesh HingoraniORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Genetic & Genomic MedicineNeurologyPeer-reviewedSep 1, 2023

Exploring the Role of Plasma Lipids and Statins Interventions on Multiple Sclerosis Risk and Severity: A Mendelian Randomization Study

Mona Mohammad Almramhi, Chris Finan, Catherine S. Storm…·Nicholas W. Wood

This study uses Mendelian randomization to investigate the causal role of lipids and statin interventions on multiple sclerosis risk and severity, finding HDL-C increases risk while RAC2 reduces it.

17 citations

humanGWAS summary statistics

𝕏 PostBluesky

GeneticsbioRxivPreprintJul 24, 2020

Finding drug targeting mechanisms with genetic evidence for Parkinson's disease -- Mendelian randomization of the druggable genome

Catherine S. Storm, Demis A. Kia, Mona Mohammad Almramhi…·Nicholas William Wood

This study uses Mendelian randomization to identify 23 potential drug targeting mechanisms for Parkinson's disease, including four drug repurposing opportunities and two drugs that may increase PD risk.

2 citations

humanGWAS summary statistics

𝕏 PostBluesky